Despite early promise and a great deal of interest in creatine
monohydrate as a possible treatment for Parkinson's disease (PD), a
large new double-blind, placebo-controlled trial found that this
treatment does not improve clinical outcomes in patients with PD.
The new findings "do not support the use of creatine" in patients with early PD treated with background dopaminergic therapy, the study authors, with corresponding author Karl Kieburtz, MD, MPH, from the University of Rochester Center for Human Experimental Therapeutics, New York, conclude.
The trial was terminated early for futility on the basis of an interim analysis of 955 participants who had completed 5 years of follow-up.
The paper, prepared by the Working Group for the Neurological Disorders and Stroke (NINDS) Exploratory Trials of Parkinson Disease, which was created to promote discovery of potential therapies, is published in the February 10 issue of JAMA.
"Unfortunately, I think this study is truly the nail in the coffin for creatine in Parkinson's disease," commented Alberto Espay, MD, associate professor, neurology, Gardner Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Ohio, and spokesperson for the International Parkinson and Movement Disorder Society, who was not part of the study group.
Nail in the Coffin?
Creatine, a nitrogenous organic acid that occurs naturally in vertebrates, helps to supply energy to cells, particularly muscle cells. It's sometimes used as a supplement by body builders to increase strength and lean muscle mass and to maximize performance.
The rationale for studying creatine in PD was that it plays an important role in cellular energy production, which is impaired in this disease. As well, animal studies had shown a neuroprotective effect, and preclinical and clinical evidence had suggested that creatine would be well tolerated.
Full report here: http://www.medscape.com/viewarticle/839567
The new findings "do not support the use of creatine" in patients with early PD treated with background dopaminergic therapy, the study authors, with corresponding author Karl Kieburtz, MD, MPH, from the University of Rochester Center for Human Experimental Therapeutics, New York, conclude.
The trial was terminated early for futility on the basis of an interim analysis of 955 participants who had completed 5 years of follow-up.
The paper, prepared by the Working Group for the Neurological Disorders and Stroke (NINDS) Exploratory Trials of Parkinson Disease, which was created to promote discovery of potential therapies, is published in the February 10 issue of JAMA.
"Unfortunately, I think this study is truly the nail in the coffin for creatine in Parkinson's disease," commented Alberto Espay, MD, associate professor, neurology, Gardner Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Ohio, and spokesperson for the International Parkinson and Movement Disorder Society, who was not part of the study group.
Nail in the Coffin?
Creatine, a nitrogenous organic acid that occurs naturally in vertebrates, helps to supply energy to cells, particularly muscle cells. It's sometimes used as a supplement by body builders to increase strength and lean muscle mass and to maximize performance.
The rationale for studying creatine in PD was that it plays an important role in cellular energy production, which is impaired in this disease. As well, animal studies had shown a neuroprotective effect, and preclinical and clinical evidence had suggested that creatine would be well tolerated.
Full report here: http://www.medscape.com/viewarticle/839567
0 comments:
Post a Comment